| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 74 | 2024 | 569 | 13.050 |
Why?
|
| Antitubercular Agents | 59 | 2023 | 343 | 6.600 |
Why?
|
| Tuberculin Test | 40 | 2023 | 132 | 5.150 |
Why?
|
| Latent Tuberculosis | 14 | 2023 | 83 | 5.070 |
Why?
|
| Tuberculosis, Pulmonary | 38 | 2021 | 250 | 4.300 |
Why?
|
| Mycobacterium tuberculosis | 36 | 2022 | 457 | 4.260 |
Why?
|
| Interferon-gamma Release Tests | 13 | 2023 | 86 | 3.560 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 8 | 2021 | 59 | 2.310 |
Why?
|
| Isoniazid | 9 | 2021 | 70 | 2.090 |
Why?
|
| Rifampin | 7 | 2021 | 145 | 2.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 12 | 2023 | 144 | 1.720 |
Why?
|
| Child | 125 | 2025 | 24063 | 1.720 |
Why?
|
| Directly Observed Therapy | 10 | 2018 | 24 | 1.520 |
Why?
|
| Child, Preschool | 77 | 2025 | 13777 | 1.500 |
Why?
|
| Mycobacterium Infections | 7 | 2010 | 31 | 1.320 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2016 | 34 | 1.200 |
Why?
|
| Mass Screening | 11 | 2021 | 778 | 1.190 |
Why?
|
| Tuberculosis, Pleural | 2 | 2022 | 10 | 1.180 |
Why?
|
| Adolescent | 72 | 2025 | 18940 | 1.150 |
Why?
|
| Humans | 175 | 2025 | 122293 | 1.140 |
Why?
|
| Infant | 58 | 2025 | 12302 | 1.130 |
Why?
|
| Lymphadenitis | 7 | 2014 | 25 | 1.030 |
Why?
|
| Tuberculosis, Meningeal | 7 | 2025 | 28 | 1.030 |
Why?
|
| Mycobacterium | 4 | 2010 | 29 | 1.020 |
Why?
|
| Contact Tracing | 5 | 2021 | 57 | 0.990 |
Why?
|
| BCG Vaccine | 8 | 2021 | 115 | 0.980 |
Why?
|
| Fever | 2 | 2019 | 295 | 0.960 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 4 | 2019 | 24 | 0.880 |
Why?
|
| Texas | 23 | 2020 | 3528 | 0.850 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2022 | 18 | 0.840 |
Why?
|
| Cost of Illness | 2 | 2014 | 239 | 0.830 |
Why?
|
| Drug Administration Schedule | 11 | 2019 | 729 | 0.820 |
Why?
|
| Mycobacterium abscessus | 2 | 2019 | 11 | 0.810 |
Why?
|
| Tuberculosis, Miliary | 2 | 2019 | 11 | 0.800 |
Why?
|
| Tuberculoma | 2 | 2019 | 4 | 0.770 |
Why?
|
| School Health Services | 4 | 2018 | 98 | 0.720 |
Why?
|
| Knee | 1 | 2019 | 15 | 0.670 |
Why?
|
| Central Nervous System Infections | 1 | 2019 | 20 | 0.650 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 10 | 0.650 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2024 | 237 | 0.630 |
Why?
|
| Drug Monitoring | 3 | 2019 | 155 | 0.630 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2019 | 79 | 0.630 |
Why?
|
| Female | 71 | 2025 | 64882 | 0.630 |
Why?
|
| Edema | 1 | 2019 | 133 | 0.620 |
Why?
|
| Male | 67 | 2025 | 59520 | 0.610 |
Why?
|
| Incidence | 17 | 2020 | 3018 | 0.610 |
Why?
|
| Medication Adherence | 5 | 2018 | 384 | 0.610 |
Why?
|
| Tuberculin | 1 | 2018 | 12 | 0.610 |
Why?
|
| Interferon-gamma | 5 | 2020 | 508 | 0.600 |
Why?
|
| Risk Factors | 28 | 2018 | 9902 | 0.600 |
Why?
|
| Infection Control | 4 | 2013 | 161 | 0.580 |
Why?
|
| Emigrants and Immigrants | 4 | 2014 | 148 | 0.570 |
Why?
|
| Hospitals, Pediatric | 9 | 2018 | 776 | 0.550 |
Why?
|
| Infant, Newborn | 21 | 2025 | 8096 | 0.520 |
Why?
|
| Professional Impairment | 1 | 2015 | 3 | 0.510 |
Why?
|
| Illness Behavior | 1 | 2015 | 8 | 0.510 |
Why?
|
| Global Health | 7 | 2025 | 555 | 0.510 |
Why?
|
| HIV Infections | 12 | 2025 | 1858 | 0.510 |
Why?
|
| Sensitivity and Specificity | 10 | 2021 | 2010 | 0.510 |
Why?
|
| Occupational Health | 1 | 2015 | 44 | 0.500 |
Why?
|
| Rat-Bite Fever | 1 | 2014 | 4 | 0.490 |
Why?
|
| Streptobacillus | 1 | 2014 | 4 | 0.490 |
Why?
|
| Arthralgia | 1 | 2014 | 45 | 0.470 |
Why?
|
| Cross Infection | 6 | 2014 | 331 | 0.460 |
Why?
|
| Age Factors | 13 | 2021 | 2777 | 0.450 |
Why?
|
| Patient Care | 1 | 2014 | 98 | 0.450 |
Why?
|
| Tuberculosis, Central Nervous System | 2 | 2007 | 11 | 0.450 |
Why?
|
| Exanthema | 1 | 2014 | 68 | 0.450 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 635 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 315 | 0.440 |
Why?
|
| Hand Hygiene | 1 | 2013 | 12 | 0.440 |
Why?
|
| Retrospective Studies | 19 | 2021 | 15853 | 0.430 |
Why?
|
| Drug Therapy | 2 | 2012 | 87 | 0.430 |
Why?
|
| Population Surveillance | 2 | 2014 | 381 | 0.410 |
Why?
|
| Anti-Bacterial Agents | 9 | 2022 | 2385 | 0.400 |
Why?
|
| Treatment Outcome | 14 | 2019 | 12044 | 0.400 |
Why?
|
| Pediatrics | 3 | 2018 | 1140 | 0.400 |
Why?
|
| Tuberculosis Vaccines | 1 | 2011 | 16 | 0.390 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 581 | 0.370 |
Why?
|
| United States | 25 | 2016 | 10487 | 0.370 |
Why?
|
| Cystic Fibrosis | 4 | 2021 | 261 | 0.360 |
Why?
|
| Drug Therapy, Combination | 9 | 2019 | 1147 | 0.350 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2010 | 5 | 0.350 |
Why?
|
| Mycobacterium avium Complex | 2 | 2019 | 22 | 0.350 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2024 | 440 | 0.340 |
Why?
|
| Vaccination | 3 | 2011 | 927 | 0.330 |
Why?
|
| Disease Management | 2 | 2016 | 511 | 0.320 |
Why?
|
| Physicians | 1 | 2015 | 582 | 0.320 |
Why?
|
| Adoption | 1 | 2008 | 16 | 0.320 |
Why?
|
| Cross Reactions | 2 | 2021 | 192 | 0.300 |
Why?
|
| Brain | 1 | 2019 | 2937 | 0.300 |
Why?
|
| Quality Improvement | 1 | 2013 | 620 | 0.290 |
Why?
|
| Diagnosis, Differential | 9 | 2014 | 1871 | 0.290 |
Why?
|
| Nontuberculous Mycobacteria | 4 | 2021 | 35 | 0.290 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 106 | 0.280 |
Why?
|
| Pyrazinamide | 3 | 2002 | 14 | 0.280 |
Why?
|
| Paresis | 1 | 2007 | 36 | 0.280 |
Why?
|
| Endemic Diseases | 1 | 2006 | 56 | 0.260 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2013 | 148 | 0.260 |
Why?
|
| Tuberculosis, Spinal | 2 | 2013 | 8 | 0.250 |
Why?
|
| Emigration and Immigration | 2 | 2004 | 81 | 0.240 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 1247 | 0.240 |
Why?
|
| Child Health Services | 2 | 2003 | 86 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 1244 | 0.240 |
Why?
|
| Patient Compliance | 4 | 2002 | 464 | 0.230 |
Why?
|
| Students | 2 | 2016 | 248 | 0.230 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 452 | 0.230 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 2817 | 0.230 |
Why?
|
| Skin Tests | 3 | 2016 | 75 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1992 | 233 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 6 | 2010 | 139 | 0.220 |
Why?
|
| Neoplasms | 3 | 2014 | 2753 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.210 |
Why?
|
| Time Factors | 3 | 2019 | 6182 | 0.210 |
Why?
|
| Clostridium Infections | 2 | 2017 | 230 | 0.210 |
Why?
|
| Models, Theoretical | 1 | 2025 | 351 | 0.210 |
Why?
|
| Pneumonia, Bacterial | 2 | 2015 | 77 | 0.200 |
Why?
|
| False Positive Reactions | 2 | 2021 | 143 | 0.200 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2014 | 23 | 0.200 |
Why?
|
| Thorax | 2 | 2019 | 73 | 0.200 |
Why?
|
| Developing Countries | 4 | 2010 | 270 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2021 | 35 | 0.190 |
Why?
|
| Radiography, Thoracic | 3 | 2011 | 156 | 0.180 |
Why?
|
| Mycobacterium avium | 1 | 2000 | 15 | 0.180 |
Why?
|
| Uterine Cervical Diseases | 1 | 2000 | 10 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2014 | 5013 | 0.180 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 1084 | 0.180 |
Why?
|
| Disease Outbreaks | 2 | 1992 | 318 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 815 | 0.170 |
Why?
|
| Reference Standards | 3 | 2015 | 240 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 3448 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2030 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 300 | 0.170 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 113 | 0.170 |
Why?
|
| Personnel, Hospital | 2 | 2013 | 35 | 0.160 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2018 | 4 | 0.160 |
Why?
|
| Surveys and Questionnaires | 5 | 2016 | 3626 | 0.160 |
Why?
|
| Rickettsia | 1 | 2018 | 11 | 0.160 |
Why?
|
| Health Personnel | 2 | 2015 | 500 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2016 | 141 | 0.150 |
Why?
|
| Debridement | 1 | 2018 | 84 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 1678 | 0.150 |
Why?
|
| Ventilators, Mechanical | 1 | 2018 | 32 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2019 | 270 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2016 | 118 | 0.150 |
Why?
|
| Health Education | 2 | 2016 | 222 | 0.150 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2016 | 793 | 0.140 |
Why?
|
| Recurrence | 4 | 2017 | 1413 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2015 | 3307 | 0.140 |
Why?
|
| Adult | 21 | 2018 | 28732 | 0.140 |
Why?
|
| Young Adult | 7 | 2023 | 8760 | 0.140 |
Why?
|
| Consensus | 4 | 2024 | 606 | 0.140 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2016 | 9 | 0.140 |
Why?
|
| Strongylida Infections | 1 | 2016 | 15 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2018 | 469 | 0.140 |
Why?
|
| Community-Acquired Infections | 2 | 2015 | 240 | 0.130 |
Why?
|
| Fever of Unknown Origin | 1 | 2016 | 45 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 384 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 145 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2014 | 309 | 0.130 |
Why?
|
| Prognosis | 7 | 2016 | 4488 | 0.130 |
Why?
|
| Prevalence | 3 | 2018 | 2371 | 0.130 |
Why?
|
| Inflammation | 2 | 2017 | 1392 | 0.130 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 1995 | 4 | 0.130 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2015 | 33 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2016 | 266 | 0.130 |
Why?
|
| Soft Tissue Infections | 2 | 2014 | 82 | 0.130 |
Why?
|
| Bacterial Vaccines | 2 | 1995 | 101 | 0.130 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 53 | 0.120 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 41 | 0.120 |
Why?
|
| Cat-Scratch Disease | 1 | 2015 | 34 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 2080 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 143 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 171 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 492 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 57 | 0.120 |
Why?
|
| Botswana | 1 | 2014 | 76 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 2 | 2010 | 50 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2018 | 995 | 0.120 |
Why?
|
| Communicable Diseases | 1 | 2016 | 163 | 0.120 |
Why?
|
| Sex Distribution | 3 | 2015 | 284 | 0.120 |
Why?
|
| Drug Costs | 1 | 2014 | 61 | 0.110 |
Why?
|
| Age Distribution | 3 | 2015 | 400 | 0.110 |
Why?
|
| Referral and Consultation | 2 | 2013 | 525 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 93 | 0.110 |
Why?
|
| Diarrhea | 1 | 2015 | 318 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 581 | 0.110 |
Why?
|
| Allografts | 1 | 2014 | 186 | 0.110 |
Why?
|
| Drug Resistance, Microbial | 4 | 1999 | 193 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 234 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 585 | 0.110 |
Why?
|
| Poverty | 1 | 2016 | 412 | 0.110 |
Why?
|
| Health Services Needs and Demand | 1 | 1994 | 171 | 0.110 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 60 | 0.100 |
Why?
|
| Family Health | 2 | 2011 | 258 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 1995 | 201 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 358 | 0.100 |
Why?
|
| Clofazimine | 2 | 2022 | 10 | 0.100 |
Why?
|
| Neck | 2 | 2008 | 134 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 1592 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 148 | 0.100 |
Why?
|
| Nephrotic Syndrome | 1 | 2012 | 47 | 0.100 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2011 | 7 | 0.100 |
Why?
|
| Markov Chains | 1 | 2012 | 79 | 0.100 |
Why?
|
| Research Design | 2 | 2013 | 646 | 0.100 |
Why?
|
| Immunization Schedule | 1 | 1991 | 102 | 0.100 |
Why?
|
| World Health Organization | 1 | 2011 | 110 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 605 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 163 | 0.090 |
Why?
|
| Cytokines | 1 | 2017 | 1272 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 805 | 0.090 |
Why?
|
| Steroids | 1 | 2012 | 203 | 0.090 |
Why?
|
| Pregnancy | 5 | 2024 | 7092 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 1234 | 0.090 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 93 | 0.090 |
Why?
|
| Mandatory Programs | 1 | 2010 | 5 | 0.090 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 296 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 179 | 0.090 |
Why?
|
| Hospitals | 1 | 2013 | 397 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2013 | 376 | 0.090 |
Why?
|
| Coinfection | 1 | 2011 | 170 | 0.090 |
Why?
|
| Public Health | 3 | 2016 | 252 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1468 | 0.080 |
Why?
|
| Carrier State | 1 | 2010 | 76 | 0.080 |
Why?
|
| Meningitis, Bacterial | 1 | 2010 | 94 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2021 | 5963 | 0.080 |
Why?
|
| Immunization | 1 | 2010 | 302 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 1991 | 263 | 0.080 |
Why?
|
| Viral Vaccines | 1 | 1991 | 322 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 4643 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1022 | 0.080 |
Why?
|
| Animals | 5 | 2018 | 33721 | 0.080 |
Why?
|
| Urban Population | 1 | 1989 | 216 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 111 | 0.080 |
Why?
|
| Radiography | 3 | 2015 | 804 | 0.080 |
Why?
|
| Biomarkers | 1 | 2017 | 2933 | 0.070 |
Why?
|
| Internationality | 1 | 2008 | 128 | 0.070 |
Why?
|
| Influenza, Human | 2 | 2010 | 646 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2008 | 130 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 371 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 220 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2008 | 215 | 0.070 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2007 | 7 | 0.070 |
Why?
|
| Bacteriological Techniques | 3 | 2012 | 90 | 0.070 |
Why?
|
| Hospitalization | 2 | 1993 | 1727 | 0.070 |
Why?
|
| Brain Diseases | 2 | 1995 | 294 | 0.070 |
Why?
|
| Amphotericin B | 1 | 1987 | 90 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 376 | 0.070 |
Why?
|
| Bacteremia | 1 | 2010 | 405 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2016 | 336 | 0.070 |
Why?
|
| Disease Progression | 2 | 2010 | 1990 | 0.060 |
Why?
|
| South Africa | 1 | 2006 | 98 | 0.060 |
Why?
|
| Candidiasis | 1 | 1987 | 129 | 0.060 |
Why?
|
| Dysentery, Bacillary | 1 | 1985 | 9 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 265 | 0.060 |
Why?
|
| Caregivers | 1 | 2011 | 561 | 0.060 |
Why?
|
| Molecular Epidemiology | 3 | 2013 | 156 | 0.060 |
Why?
|
| Colonic Diseases | 1 | 1985 | 38 | 0.060 |
Why?
|
| Ethambutol | 1 | 2004 | 8 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 1985 | 59 | 0.060 |
Why?
|
| Global Burden of Disease | 1 | 2025 | 25 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2005 | 98 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 552 | 0.060 |
Why?
|
| Thoracic Diseases | 1 | 2004 | 7 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 1987 | 239 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1283 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1109 | 0.060 |
Why?
|
| Pneumonia | 1 | 1987 | 325 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2005 | 3050 | 0.060 |
Why?
|
| Prednisone | 2 | 2016 | 273 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1679 | 0.060 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2003 | 4 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 1060 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2025 | 265 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2003 | 118 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 166 | 0.050 |
Why?
|
| Linezolid | 1 | 2022 | 36 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2002 | 32 | 0.050 |
Why?
|
| Algorithms | 3 | 2010 | 1575 | 0.050 |
Why?
|
| Visitors to Patients | 1 | 2002 | 9 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 129 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3229 | 0.050 |
Why?
|
| Ethionamide | 1 | 2002 | 1 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 237 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 200 | 0.050 |
Why?
|
| Genotype | 3 | 2016 | 2525 | 0.050 |
Why?
|
| Body Fluids | 2 | 1996 | 48 | 0.050 |
Why?
|
| Lung | 1 | 2009 | 1476 | 0.050 |
Why?
|
| Lymph Node Excision | 2 | 2000 | 157 | 0.050 |
Why?
|
| Travel | 2 | 2015 | 117 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 1995 | 480 | 0.050 |
Why?
|
| Uganda | 1 | 2021 | 70 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 1997 | 0.050 |
Why?
|
| Drug and Narcotic Control | 1 | 2020 | 18 | 0.050 |
Why?
|
| Measles | 2 | 1991 | 32 | 0.050 |
Why?
|
| Mass Chest X-Ray | 1 | 2020 | 1 | 0.050 |
Why?
|
| Sputum | 1 | 2021 | 110 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 812 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 65 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 104 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 72 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2001 | 169 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 59 | 0.040 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 62 | 0.040 |
Why?
|
| Philippines | 1 | 1997 | 23 | 0.040 |
Why?
|
| Immunocompetence | 1 | 1997 | 33 | 0.040 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 44 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 32 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 90 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 1997 | 104 | 0.030 |
Why?
|
| North America | 1 | 2016 | 234 | 0.030 |
Why?
|
| Meningitis | 1 | 2016 | 99 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 552 | 0.030 |
Why?
|
| X-Rays | 1 | 1995 | 26 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2005 | 142 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 116 | 0.030 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2015 | 16 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 941 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1995 | 118 | 0.030 |
Why?
|
| India | 1 | 2015 | 218 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2016 | 102 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1996 | 178 | 0.030 |
Why?
|
| Mastoiditis | 1 | 1995 | 31 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 421 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1995 | 155 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 445 | 0.030 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1995 | 65 | 0.030 |
Why?
|
| Hydrocephalus | 2 | 2013 | 236 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 52 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 106 | 0.030 |
Why?
|
| Tympanic Membrane | 1 | 1994 | 18 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 157 | 0.030 |
Why?
|
| Leg | 1 | 1995 | 153 | 0.030 |
Why?
|
| Automobile Driving | 1 | 1994 | 27 | 0.030 |
Why?
|
| Infliximab | 1 | 2014 | 68 | 0.030 |
Why?
|
| Middle Ear Ventilation | 1 | 1994 | 29 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 1994 | 49 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2014 | 84 | 0.030 |
Why?
|
| Head | 1 | 1994 | 101 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 373 | 0.030 |
Why?
|
| Risk-Taking | 1 | 1994 | 93 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 306 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 1997 | 592 | 0.030 |
Why?
|
| Otitis Media | 1 | 1994 | 82 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 699 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 178 | 0.030 |
Why?
|
| Violence | 1 | 1994 | 113 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 857 | 0.030 |
Why?
|
| Paraplegia | 1 | 2013 | 90 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2013 | 33 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 576 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 138 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2004 | 307 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 208 | 0.030 |
Why?
|
| Hyponatremia | 1 | 2013 | 70 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 744 | 0.030 |
Why?
|
| Societies, Medical | 1 | 1996 | 673 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2014 | 163 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 1272 | 0.020 |
Why?
|
| Skin Diseases, Infectious | 1 | 1992 | 24 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 104 | 0.020 |
Why?
|
| Diphtheria | 1 | 1991 | 15 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 386 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1993 | 226 | 0.020 |
Why?
|
| Haemophilus Infections | 1 | 1991 | 92 | 0.020 |
Why?
|
| Biopsy | 1 | 1995 | 1246 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 1991 | 130 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1993 | 313 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 125 | 0.020 |
Why?
|
| Whooping Cough | 1 | 1991 | 58 | 0.020 |
Why?
|
| Critical Illness | 1 | 2015 | 588 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 34 | 0.020 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 8 | 0.020 |
Why?
|
| Health Promotion | 1 | 1994 | 385 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2013 | 258 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1772 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1158 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 333 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1993 | 758 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2010 | 91 | 0.020 |
Why?
|
| Leukocidins | 1 | 2010 | 37 | 0.020 |
Why?
|
| Exotoxins | 1 | 2010 | 44 | 0.020 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2010 | 37 | 0.020 |
Why?
|
| HIV-1 | 1 | 1993 | 463 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 482 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1994 | 456 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1490 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1991 | 274 | 0.020 |
Why?
|
| Cambodia | 1 | 1988 | 11 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2010 | 176 | 0.020 |
Why?
|
| Encephalitis | 1 | 1990 | 111 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1994 | 604 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1994 | 1166 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1992 | 384 | 0.020 |
Why?
|
| Research | 1 | 1989 | 261 | 0.020 |
Why?
|
| Craniotomy | 1 | 1988 | 108 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1989 | 217 | 0.020 |
Why?
|
| Infectious Mononucleosis | 1 | 1987 | 15 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 550 | 0.020 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1987 | 28 | 0.020 |
Why?
|
| Hyperbilirubinemia | 1 | 1987 | 43 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1987 | 45 | 0.020 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1987 | 55 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1987 | 382 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1989 | 376 | 0.020 |
Why?
|
| Keratitis | 1 | 1987 | 116 | 0.020 |
Why?
|
| Shigella flexneri | 1 | 1985 | 13 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 100 | 0.020 |
Why?
|
| Absorption | 1 | 2004 | 52 | 0.020 |
Why?
|
| Kinetics | 1 | 1987 | 1315 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2005 | 184 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 873 | 0.010 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2004 | 23 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 668 | 0.010 |
Why?
|
| Middle Aged | 4 | 2010 | 25639 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 64 | 0.010 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Aged | 3 | 2004 | 18784 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 99 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2002 | 15 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2002 | 30 | 0.010 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2002 | 41 | 0.010 |
Why?
|
| Half-Life | 1 | 2002 | 159 | 0.010 |
Why?
|
| Family | 1 | 2005 | 565 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 668 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1987 | 4282 | 0.010 |
Why?
|
| Models, Biological | 1 | 2002 | 1438 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 2796 | 0.010 |
Why?
|
| Cranial Nerves | 1 | 1995 | 20 | 0.010 |
Why?
|
| Aging | 1 | 2002 | 1165 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 2573 | 0.010 |
Why?
|
| Granulation Tissue | 1 | 1994 | 12 | 0.010 |
Why?
|
| Mastoid | 1 | 1994 | 24 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 1994 | 44 | 0.010 |
Why?
|
| Drainage | 1 | 1994 | 254 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 3109 | 0.010 |
Why?
|
| Wound Healing | 1 | 1995 | 454 | 0.010 |
Why?
|
| Mice | 1 | 1987 | 17546 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 3865 | 0.010 |
Why?
|
| Shigella sonnei | 1 | 1987 | 3 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2997 | 0.000 |
Why?
|
| Cornea | 1 | 1987 | 645 | 0.000 |
Why?
|